What is NantOmics?
NantOmics is a prominent entity in molecular testing, focusing on the identification of genomic and proteomic alterations in cancer to guide personalized treatment strategies. The company employs an integrated panomic methodology, merging DNA sequencing, RNA sequencing, and quantitative proteomics to generate comprehensive molecular profiles for patients. This approach aims to deliver actionable intelligence and decision support to oncologists and patients, thereby advancing precision medicine by matching targeted therapies with specific tumor molecular alterations.
How much funding has NantOmics raised?
NantOmics has raised a total of $260.9M across 4 funding rounds:
Multiple Rounds
$260.9M
Private Equity (2015): $10M, investors not publicly disclosed
Private Equity (2015): $100M, investors not publicly disclosed
Private Equity (2015): $150M, investors not publicly disclosed
Private Equity (2015): $906K, investors not publicly disclosed
What's next for NantOmics?
The substantial enterprise-level backing NantOmics has received indicates a strong market confidence in its precision medicine platform. This capital infusion is likely to fuel further research and development, expansion of its analytical capabilities, and broader clinical adoption. The company is poised to enhance its role in oncology by providing deeper insights into tumor biology, facilitating more effective and personalized cancer care strategies.
See full NantOmics company page
